Auris Medical Holding AG (NASDAQ:EARS) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: September 29, 2016
Showing a price of $1.71, Auris Medical Holding AG (NASDAQ:EARS) traded -1.14% lower on the day. With the last stock price close down -48.99% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. The company has recorded a 50-day moving average of $2.16 and a 200-day moving average of $3.41. 88,490 shares of EARS traded hands, down from an average trading volume of 601,748
Zacks Investment Research has upgraded Auris Medical Holding AG (NASDAQ:EARS) to Hold in a statement released on 9/29/2016.
Recent Performance Chart
Auris Medical Holding AG has 52 week low of $1.55 and a 52 week high of $7.96 and has a market cap of $0.
A total of 4 brokers have released a ratings update on EARS. 2 analysts rating the company a strong buy, two brokerages rating the stock a buy, zero brokerages rating the stock a hold, 0 equity analysts rating the company a underperform, and finally 0 firms rating the stock a sell with a 12-month price target of $11.75.
General Company Details For Auris Medical Holding AG (NASDAQ:EARS)
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration. Its second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL). It intends to conduct over two pivotal Phase III trials in the treatment of idiopathic sudden SNHL (ISSNHL), titled Acute Inner Ear Hearing Loss (HEALOS) and Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT). AM-111 received orphan drug designation for the treatment of ASNHL from the United States Food and Drug Administration, and the European Union agency. It intends to conduct a Phase II trial in the treatment of surgery-induced hearing loss (REACH).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.